FrancophonIA/ELRC3.0 huggingface dataset:
English: The PDB includes an increase of 48 posts in the establishment plan, to a maximum number of 615 temporary agents.
Maltese: Il-PDP jinkludi żieda ta' 48 post tax-xogħol fil-pjan ta' stabbiliment, għan-numru massimu ta' 615 aġent temporanju.
English: The Board expressed its support for the vaccination strategies adapted by Member States in the wake of a potentially severe pandemic threat.
Maltese: Il-Bord esprima l-appoġġ tiegħu għall-istrateġiji tal-vaċċin adottati mill-Istati Membri meta ffaċċjati bilpossibilità ta' theddida pandemika serja.
English: Rannveig Gunnarsdóttir (Iceland)
Maltese: Rannveig Gunnarsdóttir (L-Iżlanda) Gro Ramsten Wesenberg (InNorveġja)
English: Preliminary work programme 2011
Maltese: Programm preliminari ta' ħidma 2011
English: • [EMA/MB/84539/2010] Outcome of written procedures during the period from 21 November 2009
Maltese: • [EMA/MB/84539/2010] Riżultat tal-proċeduri bil-miktub matul il-perjodu mill-21 ta' Novembru
English: Held in London on 17-18 March 2010
Maltese: Abbozz ta' aġenda għal-laqgħa tat-18 ta' Marzu 2010
English: A number of issues were raised, relating to the availability of genotoxicity data by Member States, distribution of rapporteurships among Member States, and the impact of the strict requirements of the conflicts-of-interest policy on the availability of scientific expertise.
Maltese: Tqajmu għadd ta' kwistjonijiet relatati mad-disponibilità tad-dejta dwar il-ġenotossiċità mill-Istati Membri, id-distribuzzjoni tar-‘rapporteurships' fost l-Istati Membri, u l-impatt tar-rekwiżiti stretti tal-politika tal-kunflitt ta' interess dwar id-disponibilità ta' ħila xjentifika.
English: Report from the Heads of Medicines Agencies The members noted the update report from the Heads of Medicines Agencies (HMA) on a number of topics, including:
Maltese: Rapport mill-Kapijiet tal-Aġenziji tal-Mediċini Il-membri ħadu nota tar-rapport ta' aġġornament mill-Kapijiet tal-Aġenziji tal-Mediċini (HMA) fuq għadd ta' suġġetti, inklużi:
English: [EMA/MB/818152/2009] The Management Board adopted the amendments to the Fee Regulation implementing rules.
Maltese: [EMA/MB/818152/2009] Il-Bord ta' Tmexxija adotta l-emendi għar-regoli tal-implimentazzjoni tarRegolament dwar id-Drittijiet.
English: The Chair invited members to volunteer as topic coordinators for the assessment of the Executive Director's annual activity report 2009.
Maltese: Il-President stieden lill-membri biex jivvolontarjaw bħala koordinaturi tas-suġġett għall-valutazzjoni tar-rapport tal-attivitajiet annwali tad-Direttur Eżekuttiv għas-sena 2009.
English: • [EMEA/MB/115301/2010] Annual report 2009 of the Agency's Internal Audit.
Maltese: • [EMEA/MB/115301/2010] Rapport Annwali 2009 tal-Awditjar Intern tal-Aġenzija.
English: The Board thanked the topic coordinators (Chair, Austria and the Netherlands) for their contribution in preparing these documents.
Maltese: Il-Bord irringrazzja lill-koordinaturi tas-suġġett (lill-President, lill-Awstrija u lill-Olanda) għall-kontribuzzjoni tagħhom fit-tħejjija ta' dawn id-dokumenti.
English: Some of the objectives of the action plan include:
Maltese: Uħud mill-għanijiet tal-pjan ta' azzjoni jinkludu:
English: [EMA/MB/142837/2010] The Management Board endorsed an action plan for herbal medicinal products.
Maltese: [EMA/MB/142837/2010] Il-Bord ta' Tmexxija approva pjan ta' azzjoni għall-prodotti mediċinali magħmulin mill-ħxejjex.
English: A common statement by the Heads of Medicines Agencies could help to communicate with national parliaments and bodies in light of the ongoing debate on national strategies applied during the crisis.
Maltese: Stqarrija komuni mill-Kapijiet tal-Aġenziji tal-Mediċini għandha tgħin biex tikkomunika ma' parlamenti u korpi nazzjonali fid-dawl tad-dibattitu kontinwu dwar strateġiji nazzjonali applikati matul il-kriżi.
English: Commissioner John Dalli visited the Agency on 5 March 2010.
Maltese: Il-Kummissarju John Dalli żar l-Aġenzija fil-5 ta' Marzu 2010.
English: The proportion of new marketing authorisation applications for human medicines with negative outcomes increased to 33% last year, compared to 20-25% in previous years.
Maltese: Ilproporzjon tal-applikazzjonijiet għall-awtorizzazzjoni għat-tqegħid fis-suq ta' mediċini umani b'riżultati negattivi, is-sena l-oħra żdied għal 33% meta mqabbel ma' 20-25% fis-snin ta' qabel.
English: a) Update
Maltese: a) Aġġornament
English: Revised Management Board consultation procedure for CHMP and CVMP nominations
Maltese: Proċedura riveduta ta' konsultazzjoni tal-Bord ta' Tmexxija għal nominazzjonijiet tasCHMP u tas-CVMP
English: [EMA/MB/806136/2009] The Management Board adopted the minutes with the following changes under point 12 (payment system to Member States): The Board clarified that only those countries which participated in the pilot demonstrated ability to identify hourly rates for services provided and to record time spent on centralised applications.
Maltese: [EMA/MB/806136/2009] Il-Bord ta' Tmexxija adotta l-minuti bil-bidliet li ġejjin f'punt 12 (sistema ta' ħlas lill-Istati Membri): Il-Bord ikkjarifika li dawk il-pajjiżi biss li pparteċipaw fil-proġett pilota urew abilità li jidentifikaw rati fis-siegħa għal servizzi pprovduti u li jirrekordjaw il-ħin li qattgħu fuq applikazzjonijiet ċentralizzati.
English: • progress with the HMA/EMA training strategy;
Maltese: • progress fl-istrateġija għat-taħriġ tal-HMA/EMA;
English: Expiry of the building lease in 2014
Maltese: Skadenza tal-kirja tal-bini fl-2014
English: The above trends underline the importance of the operation of policies that support small and mediumsized enterprises.
Maltese: Ix-xejriet ta' hawn fuq jenfasizzaw l-importanza tal-operazzjoni ta' politika li tappoġġja intrapriżi ta' qies żgħir u medju.
English: The Board also noted that issues exist in the area of the registration of traditional herbal medicinal products which can lead to products being marketed under another classification, e.g. food supplements.
Maltese: Il-Bord innota wkoll li jeżistu kwistjonijiet filqasam tar-reġistrazzjoni ta' prodotti mediċinali tradizzjonali magħmulin mill-ħxejjex li jistgħu jwasslu sabiex prodotti jitqiegħdu fis-suq taħt klassifikazzjoni oħra, eż. supplimenti tal-ikel.
English: The H1N1 pandemic continues to affect Africa, and EU vaccine stock is being exported to affected countries.
Maltese: Il-pandemika H1N1 qiegħda tkompli taffettwa lill-Afrika, u stokk ta' vaċċini qiegħed jiġi esportat lejn il-pajjiżi affettwati.
English: The change took place on 1 March 2010.
Maltese: Il bidla seħħet fl-1 ta' Marzu 2010.
English: The Board noted that the evaluation of the Agency commissioned by the European Commission and carried out by Ernst & Young has been completed.
Maltese: Il-Bord innota li l-evalwazzjoni tal-Aġenzija kkumissjonata mill-Kummissjoni Ewropea u magħmula minn Ernst & Young intemmet.
English: • the work of the HMA task force on improvement of veterinary legislation;
Maltese: • il-ħidma tat-task force tal-HMA dwar titjib fil-leġiżlazzjoni veterinarja;
English: Board members raised concerns about the process by which DG Sanco has apparently decided to give the mandate for vigilance of cells and tissues to ECDC.
Maltese: Kien indikat li l-mandat tal-President attwali tal-Bord ta' Tmexxija sejjer jiskadi f'Ġunju.
English: Minutes from the 65th meeting, held on 10 December 2009
Maltese: 3. Minuti mill-65 laqgħa, li saret fl-10 ta' Diċembru 2009
English: The Board also stressed that the Agency's guidance relating to new and emerging therapies is highly important in the light of scientific development.
Maltese: Il-Bord enfasizza wkoll li l-gwida tal-Aġenzija marbuta ma' terapiji ġodda u emerġenti hija importanti ħafna fid-dawl tal-iżvilupp xjentifiku.
English: The operations of the Agency and its work programme are shaped by various trends in the scientific and business environment of the Agency, including globalisation, scientific progress, and growing demand for openness and communication with stakeholders.
Maltese: L-operazzjonijiet tal-Aġenzija u l-programm ta' ħidma tagħha huma mfasslin fuq tendenzi varji flambjent xjentifiku u ta' negozju tal-Aġenzija, inkluż il-globalizzazzjoni, il-progress xjentifiku, u t-talba dejjem tikber għal attitudni miftuħa u komunikazzjoni mal-partijiet interessati.
English: The Committee discussed the overall governance arrangements of the telematics programme.
Maltese: IlKumitat iddiskuta l-arranġamenti ġenerali tat-tmexxija tal-programm telematiku.
English: [EMA/MB/75924/2010] A written procedure will be launched in April or May to amend the budget 2010.
Maltese: [EMA/MB/75924/2010] F'April jew f'Mejju sejra titnieda proċedura bil-miktub sabiex temenda l-baġit 2010.
English: The conference will address the topics raised in the evaluation and will also be an opportunity to discuss key issues proposed in the Agency's draft road map to 2015.
Maltese: Il-konferenza sejra tindirizza t-temi mqajma fl-evalwazzjoni u sejra tkun ukoll opportunità sabiex jiġu diskussi l-kwistjonijiet ewlenin proposti fl-abbozz tal-Pjan Direzzjonali tal-Aġenzija sal-2015.
English: The MBTC and Heads of Medicines Agencies telematics group will work to ensure optimum collaboration.
Maltese: Il-Kumitat ra preżentazzjonijiet mill-presidenti tal-gruppi ta' implimentazzjoni tat-telematika.
English: [EMA/MB/69923/2010] The Management Board adopted the Agency's annual report 2009.
Maltese: [EMA/MB/69923/2010] Il-Bord ta' Tmexxija adotta r-rapport annwali tal-Aġenzija għas-sena 2009.
English: • [EMEA/MB/115245/2010] Annual report 2009 of the Agency's Audit Advisory Committee.
Maltese: • [EMEA/MB/115245/2010] Rapport Annwali 2009 tal-Kumitat tal-Aġenzija għall-Pariri dwar l
English: The amendments concern the adjustment of fees to inflation (increase by 1%), establishing reduced fees for applications for marketing authorisation for multi-strain dossiers, adapting the fees for extensions of marketing authorisations and clarifying reporting requirements for national competent authorities.
Maltese: L-emendi jikkonċernaw l-aġġustament tad-drittijiet għall-inflazzjoni (żieda ta' 1%), l-istabbiliment ta' drittijiet imnaqqsa għall-applikazzjonijiet għall-awtorizzazzjoni għattqegħid fis-suq għal dossiers dwar aktar minn razza waħda, l-addattament tal-ħlasijiet għallestensjonijiet tal-awtorizzazzjoni għat-tqegħid fis-suq u l-kjarifika tar-rekwiżiti tar-rappurtaġġ lill awtoritajiet nazzjonali kompetenti.
English: The Board discussed the need to enhance the number of list entries, but noted the hurdles posed by the unavailability of genotoxicity data.
Maltese: Il-Bord iddiskuta l-ħtieġa li jtejjeb in-numru ta' oġġetti fil-lista iżda nnota l-intoppi minħabba n-nuqqas ta' disponibilità ta' dejta dwar il-ġenotossiċità.
English: Date of first authorisation: 14 September 1998 Date of latest renewal: 14 September 2008
Maltese: Data tal-ewwel awtorizzazzjoni: 14 ta' Settembru 1998 Data tal-aħħar tiġdid: 14 ta' Settembru 2008
English: The manufacturer of VIAGRA is Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Pocé-sur-Cisse, France.
Maltese: Il-manifattur ta' VIAGRA huwa Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Pocé-sur-Cisse, Franza.
English: Rare ( 1/10,000 and
Maltese: Rari ( 1/10,000 u
English: The N-desmethyl metabolite is further metabolised, with a terminal half-life of approximately 4 h.
Maltese: Ilmetabolu N-desmethyl jiġi mmetabolizzat iżjed, b'half life terminali ta' bejn wieħed u ieħor 4 h.
English: Flavouring contains: Maltodextrin Dextrin
Maltese: It-togħma fiha: Maltodextrin Dextrin
English: Glycerol (E422) Propylene glycol (E1520)
Maltese: It-togħma naturali fiha: Maltodextrin Glycerol (E422) Propylene glycol (E1520)
English: In clinical trials sildenafil was administered to more than 8000 patients aged 19-87.
Maltese: Fi provi kliniċi sildenafil ġie mogħti lil aktar minn 8000 pazjent ta' età 19 - 87 sena.
English: Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 > 150 μM).
Maltese: Sildenafil huwa inibitur dgħajjef ta' ċitokromju P450 iżoformi 1A2, 2C9, 2C19, 2D6, 2E1 u 3A4 ( 1C50 > 150 µM).
English: Sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates.
Maltese: Sildenafil (100 mg) ma affettwax il-farmakokinetika fi stat stabbli ta' l-inibituri ta' HIV protease, saquinavir u ritonavir, it-tnejn li huma sustrati CYP3A4.
English: Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP.
Maltese: Sildenafil huwa inibitur potenti u selettiv ta' cGMP specific phosphodiesterase type 5 (PDE5) filcorpus cavernosum, fejn PDE5 huwa responsabbli għad-degradazzjoni ta' cGMP.
English: Across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84%), mixed erectile dysfunction (77%), organic erectile dysfunction (68%), elderly (67%), diabetes mellitus (59%), ischaemic heart disease (69%), hypertension (68%), TURP (61%), radical prostatectomy (43%), spinal cord injury (83%), depression (75%).
Maltese: Fil-provi kollha, il-proporzjon ta' pazjenti li rrappurtaw titjib b'sildenafil kienu kif ġejjin: problema ta' erezzjoni tal-pene psikoġenika (84%), problemi ta' l-erezzjoni mħallta (77%), problema ta' erezzjoni organika (68%), anzjani (67%), dijabetiċi (59%), mard iskemiku tal-qalb (69%), pressjoni għolja (68%), TURP (61%), prostatectomy radikali (43%), korriment fis-sinsla tad-dahar (83%), dipressjoni (75%).
English: The other ingredients are: microcrystalline cellulose, silica hydrophobic colloidal, croscarmellose sodium, magnesium stearate, indigo carmine aluminium lake (E132), sucralose, mannitol, crospovidone, polyvinyl acetate, povidone, flavouring containing: maltodextrin and dextrin, natural flavouring containing: maltodextrin, glycerol (E422) and propylene glycol (E1520), lemon flavouring containing: maltodextrin and alpha-tocopherol (E307)).
Maltese: Is-sustanzi l-oħra huma: microcrystalline cellulose, silica hydrophobic colloidal , croscarmellose sodium, magnesium stearate, indigo carmine aluminium lake (E132), sucralose, mannitol, crospovidone, polyvinyl acetate, povidone, togħma li fiha: maltodextrin u dextrin, togħma naturali li fiha: maltodextrin, glycerol (E422) u propylene glycol (E1520), togħma tal-lumi li fiha: maltodextrin u alpha-tocopherol (E307)).
English: Paediatric population VIAGRA is not indicated for individuals below 18 years of age.
Maltese: Popolazzjoni pedjatrika VIAGRA mhix indikata għal individwi taħt l-età ta' 18 sena.
English: VIAGRA 50 mg tablets Each tablet contains 1.667 mg lactose (as monohydrate).
Maltese: VIAGRA 50 mg pilloli Kull pillola fiha 1.667 mg ta' lactose (bħala monohydrate).
English: Alpha-tocopherol (E307)
Maltese: It-togħma tal-lumi fiha: Maltodextrin Alpha-tocopherol (E307)
English: Epistaxis, Sinus congestion
Maltese: Epistassi, Konġestjoni tas-sinus
English: The safety profile of VIAGRA is based on 9,570 patients in 74 double-blind placebo-controlled clinical studies.
Maltese: Is-sigurta' ta' VIAGRA hija bbażata fuq 9,570 pazjent f'74 studji klinici kkontrollati bi plaċebo double-blind.
English: Sildenafil had no effect on saquinavir pharmacokinetics (see section 4.2).
Maltese: Sildenafil ma kellux effett fuq il-farmakokinetika ta' saquinavir (ara sezzjoni 4.2).
English: Contains lactose See package leaflet for further information
Maltese: Kontenut tal-pakkett u informazzjoni oħra
English: This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% that of the parent drug.
Maltese: Dan il-metabolu għandu profil selettiv ta' phosphodiesterase simili għal sildenafil u potenza in vitro għal PDE5 bejn wieħed u ieħor 50% ta' dik tal-mediċina mhux mibdula.
English: VIAGRA with alcohol
Maltese: VIAGRA ma' alkoħol
English: Tablet core: microcrystalline cellulose calcium hydrogen phosphate (anhydrous) croscarmellose sodium magnesium stearate
Maltese: Qalba tal-pillola: microcrystalline cellulose calcium hydrogen phosphate (anhydrous), croscarmellose sodium magnesium stearate
English: Film coat: hypromellose titanium dioxide (E171) lactose monohydrate triacetin indigo carmine aluminium lake (E132)
Maltese: Kisja tar-rita: hypromellose titanium dioxide (E171) lactose monohydrate triacetin indigo carmine aluminium lake (E132)
English: The active substance is sildenafil.
Maltese: Is-sustanza attiva hi s-sildenafil.
English: VIAGRA 100 mg tablets Each tablet contains 3.334 mg lactose (as monohydrate).
Maltese: VIAGRA 100 mg pilloli Kull pillola fiha 3.334 mg ta' lactose (bħala monohydrate).
English: Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state.
Maltese: L-ogħla konċentrazzjonijiet osservati fil-plażma intlaħqu fi żmien 30 sa 120 minuta (medjan 60 minuta) ta' doża orali fi stat sajjem.
English: VIAGRA should not be administered to men with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Maltese: VIAGRA m'għandhiex tingħata lill-irġiel li għandhom problemi ereditarji ta' intolleranza għall-galactose, defiċjenza ta' lactase tip Lapp jew li għandhom problemi flassorbiment ta' glucose-galactose.
English: VIAGRA contains lactose
Maltese: VIAGRA fih lactose
English: VIAGRA 25 mg tablets Each tablet contains 0.834 mg lactose (as monohydrate).
Maltese: VIAGRA 25 mg pilloli Kull pillola fiha 0.834 mg ta' lactose (bħala monohydrate).
English: VIAGRA 100 mg film-coated tablets EU/1/98/077/010-012
Maltese: VIAGRA 100 mg pilloli miksija b'rita EU/1/98/077/010-012
English: In these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were observed.
Maltese: F'dawn il-popolazjonijiet ta' l-istudji, kien osservat tnaqqis addizzjonali medju talpressjoni meta kienu mimdudin ta' 7/7mmHg, 9/5mmHg u 8/4mmHg rispettivament u meta bil-wieqfa tnaqqis addizzjonali medju ta' 6/6mmHg, 11/4mmHg u 4/5nnHg.
English: Syndrome (SJS)*, Toxic
Maltese: Sindromu ta' StevensJohnson (SJS)*, Nekrolisi tossika tal-ġilda (TEN)
English: VIAGRA 25 mg film-coated tablets EU/1/98/077/002-004
Maltese: VIAGRA 25 mg pilloli miksija b'rita EU/1/98/077/002-004
English: VIAGRA 50 mg film-coated tablets EU/1/98/077/006-008
Maltese: VIAGRA 50 mg pilloli miksija b'rita EU/1/98/077/006-008
English: There is a 10-fold selectivity over PDE6 which is involved in the phototransduction pathway in the retina.
Maltese: Hemm selettività ta' għaxar darbiet fuq PDE6 li huwa nvolut fil- phototransduction pathway fir-retina.
English: The other ingredients are: Tablet core: microcrystalline cellulose, calcium hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate,
Maltese: microcrystalline cellulose, calcium hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate,
English: hypromellose, titanium dioxide (E171), lactose monohydrate, triacetin,
Maltese: hypromellose, titanium dioxide (E171), lactose monohydrate, triacetin, indigo carmine aluminium lake (E132)
English: Single doses of antacid (magnesium hydroxide/aluminium hydroxide) did not affect the bioavailability of sildenafil.
Maltese: Doża waħda ta' mediċina kontra l-aċidu fl-istonku (magnesium hydroxide/ aluminium hydroxide) ma effettwatx il-biodisponibilità ta' sildenafil.
English: No significant interactions were shown when sildenafil (50 mg) was co-administered with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolised by CYP2C9.
Maltese: Ma kienx hemm interazzjonijiet sinifikanti meta sildenafil (50 mg) kien ko-amministrat ma' tolbutamide (250 mg) jew warfarin (40 mg), li t-tnejn li huma jiġu mmetabolizzati minn CYP2C9.
English: Marketing Authorisation Holder and Manufacturer The marketing authorisation holder of VIAGRA is Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium.
Maltese: Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq u l-Manifattur Id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq ta' VIAGRA huwa Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, il-Belġju.
English: In fixed dose studies, the proportions of patients reporting that treatment improved their erections were 62% (25 mg), 74% (50 mg) and 82% (100 mg) compared to 25% on placebo.
Maltese: Fi studji ta' doża fissa, il-proporzjon ta' pazjenti li rrappurtaw li l-kura tejjbet l-erezzjonijiet tagħhom kienu 62% (25 mg), 74% (50 mg), u 82% (100 mg) imqabbla ma' 25% fuq il-plaċebo.
English: In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.
Maltese: Fi tliet studji speċifiċi għal interazzjoni bejn żewġ prodotti mediċinali, alpha blocker doxazocin (4mg u 8mg) u sildenafil (25mg, 50mg u 100mg) ġew amministrati fl-istess ħin lil pazjenti bi tkabbir beninju tal-prostata (BPH), stabilizzati fuq kura b' doxazocin.
English: • Seizures or fits - this occurs rarely
Maltese: • Reazzjonijiet serji tal-ġilda - dawn iseħħu b'mod rari
English: The following patient groups were represented: elderly (19.9%), patients with hypertension (30.9%), diabetes mellitus (20.3%), ischaemic heart disease (5.8%), hyperlipidaemia (19.8%), spinal cord injury (0.6%), depression (5.2%), transurethral resection of the prostate (3.7%), radical prostatectomy (3.3%).
Maltese: 3%), b'mard iskemiku tal-qalb (5.8%), iperlipidimja (19.8%), ħsara fis-sinsla tad-dahar (0.6%), dipressjoni (5.2%), b'resezzjoni transuretrali tal-prostata (3.7%), prostatectomy radikali (3.3%).
English: Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes.
Maltese: Sildenafil huwa mneħħi primarjament mill-iżo-enżimi mikrożomali CYP3A4 (rotta ewlenija) u CYP2C9 (rotta minuri) tal-fwied.
English: VIAGRA with food and drink and alcohol
Maltese: VIAGRA ma' ikel, xorb u alkoħol
English: Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates).
Maltese: Għalkemm ma sarux studji speċifiċi ta' interazzjoni għal prodotti mediċinali kollha, analiżi talfarmakokinetika tal-popolazzjoni ma juru l-ebda effett ta' kura konkomitanti fuq il-farmakokinetika ta' sildenafil meta miġbura fi gruppi bħala inibituri ta' CYP2C9 (bħal tolbutamide, warfarin, phenytoin), inibituri ta' CYP2D6 (bħal selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide u dijuretiċi relatati, dijuretiċi loop u potassium-sparing, inibituri ta' l-enżima li tikkonverti langiotensin, channel blockers tal-kalċju, antagonisti beta-adrenoreceptor jew inducers tal-metaboliżu CYP450 ( bħal rifampicin, barbiturate).
English: Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by acetyl salicylic acid (150 mg).
Maltese: Sildenafil (50 mg) ma saħħaħx iż-żieda fil-ħin tal-fsada kkaġunat mill-aċidu acetyl salicyclic (150 mg).
English: VIAGRA contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Maltese: VIAGRA fih is-sustanza attiva sildenafil li jagħmel ma' grupp ta' mediċinali msejħa inibituri ta' phosphodiesterase type 5(PDE5).